-
1 Comment
Accelerate Diagnostics, Inc is currently in a long term downtrend where the price is trading 19.7% below its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 44.6.
Accelerate Diagnostics, Inc's total revenue sank by 10.4% to $3M since the same quarter in the previous year.
Its net income has increased by 11.4% to $-19M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.4% to $-10M since the same quarter in the previous year.
Based on the above factors, Accelerate Diagnostics, Inc gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Medical Devices |
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | US00430H1023 |
Beta | 0.46 |
---|---|
Market Cap | 14M |
PE Ratio | None |
Target Price | 1.5 |
Dividend Yield | None |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, is indicated as an aid, in the diagnosis of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. Further, it provides the Accelerate Arc system, an instrument and associated one-time-use test kit that automates the clean-up and concentration of microbial cells from positive blood culture samples. Additionally, it offers Accelerate WAVE system, a clinical trial product, performs AST directly from positive blood culture bottles and bacterial isolate colonies to report minimum inhibitory concentrations, based on the principle of digital holographic microscopy, which allows for simultaneous volumetric imaging of a sample suspension at a high spatial resolution, enabling direct observation of phenotypic responses of individual bacterial cells. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AXDX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025